Clinical characteristics and β-blocker therapy in 30 CPVT mutation carriers diagnosed by cascade genetic screening
| Age (years) | 32 (6–75) |
| Females ( n ) | 16 (53%) |
| Follow-up (months) | 22 (13–288) |
| Heterozygous G2337V carriers ( n ) | 16 |
| Heterozygous G4671 carriers ( n ) | 6 |
| Heterozygous A2387V carriers ( n ) | 6 |
| Heterozygous R176Q carriers ( n ) | 2 |
| ICD ( n ) | 3 |
| β-Blocker therapy | |
| Metoprololsuccinate ( n = 17) (mg) | 125 ± 50 |
| Nadolol ( n = 10/ n = 7, children excluded) (mg) | 77 ± 34/90 ± 30 |
| Carvedilol ( n = 1) (mg) | 25 |
| Bisoprolol ( n = 1) (mg) | 10 |
| Propranolol ( n = 1) (mg) | 120 |
| Age (years) | 32 (6–75) |
| Females ( n ) | 16 (53%) |
| Follow-up (months) | 22 (13–288) |
| Heterozygous G2337V carriers ( n ) | 16 |
| Heterozygous G4671 carriers ( n ) | 6 |
| Heterozygous A2387V carriers ( n ) | 6 |
| Heterozygous R176Q carriers ( n ) | 2 |
| ICD ( n ) | 3 |
| β-Blocker therapy | |
| Metoprololsuccinate ( n = 17) (mg) | 125 ± 50 |
| Nadolol ( n = 10/ n = 7, children excluded) (mg) | 77 ± 34/90 ± 30 |
| Carvedilol ( n = 1) (mg) | 25 |
| Bisoprolol ( n = 1) (mg) | 10 |
| Propranolol ( n = 1) (mg) | 120 |
Median (range), mean ± SD.
Clinical characteristics and β-blocker therapy in 30 CPVT mutation carriers diagnosed by cascade genetic screening
| Age (years) | 32 (6–75) |
| Females ( n ) | 16 (53%) |
| Follow-up (months) | 22 (13–288) |
| Heterozygous G2337V carriers ( n ) | 16 |
| Heterozygous G4671 carriers ( n ) | 6 |
| Heterozygous A2387V carriers ( n ) | 6 |
| Heterozygous R176Q carriers ( n ) | 2 |
| ICD ( n ) | 3 |
| β-Blocker therapy | |
| Metoprololsuccinate ( n = 17) (mg) | 125 ± 50 |
| Nadolol ( n = 10/ n = 7, children excluded) (mg) | 77 ± 34/90 ± 30 |
| Carvedilol ( n = 1) (mg) | 25 |
| Bisoprolol ( n = 1) (mg) | 10 |
| Propranolol ( n = 1) (mg) | 120 |
| Age (years) | 32 (6–75) |
| Females ( n ) | 16 (53%) |
| Follow-up (months) | 22 (13–288) |
| Heterozygous G2337V carriers ( n ) | 16 |
| Heterozygous G4671 carriers ( n ) | 6 |
| Heterozygous A2387V carriers ( n ) | 6 |
| Heterozygous R176Q carriers ( n ) | 2 |
| ICD ( n ) | 3 |
| β-Blocker therapy | |
| Metoprololsuccinate ( n = 17) (mg) | 125 ± 50 |
| Nadolol ( n = 10/ n = 7, children excluded) (mg) | 77 ± 34/90 ± 30 |
| Carvedilol ( n = 1) (mg) | 25 |
| Bisoprolol ( n = 1) (mg) | 10 |
| Propranolol ( n = 1) (mg) | 120 |
Median (range), mean ± SD.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
